| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase Inhibitors | 50 | 2024 | 5672 | 3.260 |
Why?
|
| Antineoplastic Agents | 71 | 2023 | 13642 | 2.950 |
Why?
|
| Pyrazines | 12 | 2024 | 1202 | 2.690 |
Why?
|
| Neoplasms | 69 | 2024 | 22173 | 2.620 |
Why?
|
| Pyrazoles | 19 | 2021 | 2009 | 2.520 |
Why?
|
| Cyclin-Dependent Kinases | 14 | 2024 | 655 | 2.400 |
Why?
|
| HSP90 Heat-Shock Proteins | 14 | 2021 | 424 | 2.140 |
Why?
|
| Cyclin-Dependent Kinase 4 | 12 | 2024 | 561 | 2.120 |
Why?
|
| Cyclin-Dependent Kinase 6 | 9 | 2019 | 350 | 2.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2024 | 11742 | 2.040 |
Why?
|
| Piperidines | 15 | 2020 | 1656 | 1.830 |
Why?
|
| Maximum Tolerated Dose | 31 | 2021 | 883 | 1.820 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 48 | 2023 | 5314 | 1.690 |
Why?
|
| Ovarian Neoplasms | 19 | 2024 | 4878 | 1.650 |
Why?
|
| Benzimidazoles | 6 | 2021 | 858 | 1.510 |
Why?
|
| Piperazines | 12 | 2024 | 2523 | 1.460 |
Why?
|
| BRCA1 Protein | 10 | 2024 | 1158 | 1.440 |
Why?
|
| Sulfonamides | 11 | 2024 | 1979 | 1.430 |
Why?
|
| Cystadenocarcinoma, Serous | 5 | 2021 | 478 | 1.410 |
Why?
|
| Lung Neoplasms | 62 | 2023 | 13381 | 1.350 |
Why?
|
| Pyrimidines | 13 | 2020 | 3028 | 1.350 |
Why?
|
| CDC2 Protein Kinase | 6 | 2018 | 213 | 1.340 |
Why?
|
| Cisplatin | 9 | 2021 | 1652 | 1.310 |
Why?
|
| Azetidines | 3 | 2020 | 142 | 1.290 |
Why?
|
| Phthalazines | 6 | 2024 | 383 | 1.290 |
Why?
|
| Isoindoles | 2 | 2020 | 35 | 1.210 |
Why?
|
| Isoxazoles | 5 | 2024 | 232 | 1.170 |
Why?
|
| Pyridines | 16 | 2020 | 2875 | 1.160 |
Why?
|
| Pyrimidinones | 4 | 2024 | 385 | 1.070 |
Why?
|
| Drug Resistance, Neoplasm | 23 | 2024 | 5305 | 1.050 |
Why?
|
| DNA Damage | 14 | 2023 | 2449 | 1.030 |
Why?
|
| Azepines | 2 | 2020 | 329 | 1.010 |
Why?
|
| Deoxycytidine | 9 | 2024 | 877 | 0.980 |
Why?
|
| Flavonoids | 10 | 2013 | 445 | 0.950 |
Why?
|
| Quinazolines | 17 | 2024 | 1371 | 0.930 |
Why?
|
| Aniline Compounds | 5 | 2024 | 1069 | 0.920 |
Why?
|
| DNA Repair | 16 | 2024 | 2046 | 0.910 |
Why?
|
| Enzyme Inhibitors | 15 | 2018 | 3713 | 0.880 |
Why?
|
| Benzamides | 3 | 2020 | 1371 | 0.880 |
Why?
|
| Food-Drug Interactions | 3 | 2018 | 24 | 0.850 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2024 | 1745 | 0.840 |
Why?
|
| Nuclear Proteins | 14 | 2023 | 5799 | 0.830 |
Why?
|
| Drug Administration Schedule | 18 | 2021 | 4853 | 0.820 |
Why?
|
| bcl-X Protein | 1 | 2024 | 410 | 0.810 |
Why?
|
| Pyridones | 3 | 2024 | 809 | 0.780 |
Why?
|
| Cell Cycle Proteins | 16 | 2023 | 3449 | 0.780 |
Why?
|
| Proto-Oncogene Proteins c-met | 9 | 2019 | 571 | 0.760 |
Why?
|
| Mutation | 32 | 2024 | 30053 | 0.760 |
Why?
|
| Aminopyridines | 5 | 2023 | 573 | 0.760 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2023 | 1728 | 0.750 |
Why?
|
| Protein-Tyrosine Kinases | 14 | 2023 | 2425 | 0.740 |
Why?
|
| Indazoles | 4 | 2020 | 304 | 0.710 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 2023 | 489 | 0.710 |
Why?
|
| Cell Cycle | 15 | 2024 | 2932 | 0.690 |
Why?
|
| Cell Line, Tumor | 45 | 2024 | 16990 | 0.690 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 12 | 2021 | 1626 | 0.690 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2013 | 237 | 0.690 |
Why?
|
| Quinolines | 11 | 2015 | 765 | 0.670 |
Why?
|
| Apoptosis | 17 | 2024 | 9490 | 0.670 |
Why?
|
| Dose-Response Relationship, Drug | 28 | 2020 | 10766 | 0.660 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 3617 | 0.660 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 5 | 2023 | 641 | 0.660 |
Why?
|
| Triazoles | 3 | 2013 | 903 | 0.640 |
Why?
|
| Anilides | 4 | 2018 | 411 | 0.630 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 1405 | 0.630 |
Why?
|
| Xenograft Model Antitumor Assays | 20 | 2024 | 3605 | 0.610 |
Why?
|
| Camptothecin | 3 | 2016 | 591 | 0.590 |
Why?
|
| DNA Replication | 5 | 2024 | 1418 | 0.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 21 | 2024 | 8554 | 0.590 |
Why?
|
| Pancreatic Neoplasms | 7 | 2023 | 5368 | 0.580 |
Why?
|
| S Phase | 4 | 2009 | 421 | 0.570 |
Why?
|
| Cyclin-Dependent Kinase 2 | 4 | 2006 | 184 | 0.570 |
Why?
|
| Benzoquinones | 5 | 2013 | 198 | 0.570 |
Why?
|
| Cyclins | 2 | 2017 | 594 | 0.560 |
Why?
|
| Humans | 208 | 2024 | 761596 | 0.550 |
Why?
|
| Aged | 90 | 2024 | 169310 | 0.550 |
Why?
|
| Carcinoma | 3 | 2023 | 2330 | 0.540 |
Why?
|
| Immunoconjugates | 3 | 2020 | 953 | 0.530 |
Why?
|
| Lactams, Macrocyclic | 5 | 2013 | 318 | 0.520 |
Why?
|
| Poly(ADP-ribose) Polymerases | 5 | 2023 | 426 | 0.520 |
Why?
|
| Aged, 80 and over | 46 | 2024 | 58984 | 0.510 |
Why?
|
| Middle Aged | 92 | 2024 | 220921 | 0.500 |
Why?
|
| Female | 120 | 2024 | 392705 | 0.500 |
Why?
|
| Triazines | 2 | 2015 | 311 | 0.500 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2014 | 92 | 0.500 |
Why?
|
| Indoles | 5 | 2024 | 1833 | 0.500 |
Why?
|
| Oligopeptides | 2 | 2020 | 1187 | 0.490 |
Why?
|
| Quinoxalines | 2 | 2014 | 296 | 0.480 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 9 | 2016 | 698 | 0.480 |
Why?
|
| TOR Serine-Threonine Kinases | 9 | 2021 | 2057 | 0.470 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2022 | 2917 | 0.470 |
Why?
|
| Organic Chemicals | 1 | 2015 | 210 | 0.470 |
Why?
|
| Morpholines | 2 | 2015 | 581 | 0.470 |
Why?
|
| Treatment Outcome | 47 | 2024 | 64685 | 0.460 |
Why?
|
| Transforming Growth Factor beta | 3 | 2019 | 1964 | 0.460 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2014 | 332 | 0.440 |
Why?
|
| Adult | 78 | 2024 | 221210 | 0.440 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2010 | 67 | 0.430 |
Why?
|
| DNA, Single-Stranded | 2 | 2024 | 355 | 0.410 |
Why?
|
| Male | 95 | 2024 | 360846 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2023 | 4514 | 0.410 |
Why?
|
| Administration, Oral | 11 | 2021 | 4021 | 0.400 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 476 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 6 | 2021 | 2811 | 0.390 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2023 | 4580 | 0.380 |
Why?
|
| Neoplasm Staging | 17 | 2020 | 11120 | 0.380 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2023 | 1062 | 0.370 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 335 | 0.370 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2012 | 678 | 0.370 |
Why?
|
| cdc25 Phosphatases | 1 | 2011 | 60 | 0.370 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 304 | 0.370 |
Why?
|
| Signal Transduction | 22 | 2024 | 23447 | 0.360 |
Why?
|
| Tumor Microenvironment | 7 | 2023 | 3878 | 0.360 |
Why?
|
| Oncogene Proteins, Fusion | 8 | 2023 | 1609 | 0.350 |
Why?
|
| Phosphorylation | 15 | 2020 | 8321 | 0.350 |
Why?
|
| Area Under Curve | 9 | 2015 | 1638 | 0.350 |
Why?
|
| Hydroxamic Acids | 3 | 2013 | 481 | 0.350 |
Why?
|
| MAP Kinase Signaling System | 3 | 2020 | 1486 | 0.340 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2012 | 774 | 0.340 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2010 | 80 | 0.340 |
Why?
|
| Cyclin-Dependent Kinase 9 | 2 | 2006 | 67 | 0.320 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 457 | 0.320 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 287 | 0.320 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1993 | 0.320 |
Why?
|
| Adenocarcinoma | 7 | 2023 | 6345 | 0.310 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 617 | 0.310 |
Why?
|
| GTP Phosphohydrolases | 2 | 2024 | 517 | 0.310 |
Why?
|
| E2F1 Transcription Factor | 2 | 2006 | 178 | 0.310 |
Why?
|
| Neoplasm Metastasis | 12 | 2020 | 4915 | 0.300 |
Why?
|
| Gene Rearrangement | 5 | 2019 | 1125 | 0.290 |
Why?
|
| Transcription Factors | 7 | 2023 | 12130 | 0.290 |
Why?
|
| Food | 2 | 2011 | 774 | 0.290 |
Why?
|
| Animals | 58 | 2024 | 168475 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 4024 | 0.280 |
Why?
|
| Infusions, Intravenous | 7 | 2020 | 2217 | 0.280 |
Why?
|
| Retinoblastoma Protein | 7 | 2010 | 672 | 0.270 |
Why?
|
| G1 Phase | 4 | 2006 | 403 | 0.270 |
Why?
|
| Membrane Proteins | 3 | 2019 | 7859 | 0.270 |
Why?
|
| Quinones | 2 | 2005 | 78 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2024 | 988 | 0.260 |
Why?
|
| Mice | 45 | 2024 | 81539 | 0.260 |
Why?
|
| Phenylurea Compounds | 3 | 2019 | 529 | 0.260 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3701 | 0.260 |
Why?
|
| Proteins | 1 | 2020 | 6032 | 0.260 |
Why?
|
| Doxorubicin | 1 | 2012 | 2224 | 0.260 |
Why?
|
| Drug Synergism | 4 | 2019 | 1757 | 0.250 |
Why?
|
| Drug Design | 1 | 2010 | 1048 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2014 | 2223 | 0.240 |
Why?
|
| Breast Neoplasms | 10 | 2024 | 21019 | 0.240 |
Why?
|
| RNA, Small Interfering | 6 | 2016 | 3430 | 0.240 |
Why?
|
| Pyridinium Compounds | 2 | 2016 | 81 | 0.240 |
Why?
|
| Glycoside Hydrolases | 1 | 2024 | 135 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2012 | 546 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2020 | 1246 | 0.230 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2004 | 110 | 0.220 |
Why?
|
| BRCA2 Protein | 3 | 2020 | 805 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2022 | 2865 | 0.220 |
Why?
|
| Mucin-1 | 2 | 2023 | 540 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 9280 | 0.220 |
Why?
|
| Receptor, erbB-2 | 7 | 2013 | 2557 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 899 | 0.210 |
Why?
|
| Stress, Physiological | 1 | 2010 | 1403 | 0.210 |
Why?
|
| MicroRNAs | 1 | 2019 | 3816 | 0.210 |
Why?
|
| DNA-Binding Proteins | 7 | 2023 | 9610 | 0.210 |
Why?
|
| Genomics | 6 | 2023 | 5821 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 7 | 2017 | 9177 | 0.210 |
Why?
|
| Carboplatin | 6 | 2018 | 794 | 0.200 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2012 | 423 | 0.200 |
Why?
|
| Chromones | 1 | 2022 | 148 | 0.200 |
Why?
|
| Carrier Proteins | 5 | 2011 | 4937 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 11 | 2020 | 6131 | 0.200 |
Why?
|
| G2 Phase | 3 | 2011 | 136 | 0.200 |
Why?
|
| ras Proteins | 3 | 2017 | 1054 | 0.200 |
Why?
|
| Nausea | 4 | 2013 | 679 | 0.200 |
Why?
|
| Mitosis | 3 | 2021 | 1188 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2014 | 326 | 0.190 |
Why?
|
| Drug Monitoring | 3 | 2020 | 962 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 2048 | 0.190 |
Why?
|
| Pyrroles | 3 | 2017 | 1125 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2017 | 473 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2017 | 477 | 0.190 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.190 |
Why?
|
| Salvage Therapy | 3 | 2020 | 1263 | 0.180 |
Why?
|
| Genes, p16 | 2 | 2007 | 160 | 0.180 |
Why?
|
| Protein Kinases | 2 | 2008 | 1608 | 0.180 |
Why?
|
| DNA, Neoplasm | 6 | 2010 | 1745 | 0.180 |
Why?
|
| Melanoma | 5 | 2023 | 5709 | 0.180 |
Why?
|
| Thiazoles | 3 | 2022 | 1517 | 0.180 |
Why?
|
| Platinum | 3 | 2020 | 220 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 2894 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 214 | 0.170 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2020 | 123 | 0.170 |
Why?
|
| Imidazoles | 1 | 2006 | 1180 | 0.170 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2022 | 112 | 0.170 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 6815 | 0.170 |
Why?
|
| Indolizines | 2 | 2016 | 30 | 0.170 |
Why?
|
| Cyclic N-Oxides | 2 | 2016 | 72 | 0.160 |
Why?
|
| Mice, SCID | 5 | 2020 | 2626 | 0.160 |
Why?
|
| Ataxia Telangiectasia | 1 | 2020 | 107 | 0.160 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2014 | 620 | 0.160 |
Why?
|
| Drug Discovery | 3 | 2015 | 1051 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2014 | 1406 | 0.160 |
Why?
|
| Fasting | 2 | 2018 | 1603 | 0.160 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 11076 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2011 | 5112 | 0.160 |
Why?
|
| Prognosis | 13 | 2021 | 29629 | 0.160 |
Why?
|
| Vomiting | 2 | 2012 | 651 | 0.160 |
Why?
|
| Phenylenediamines | 1 | 2018 | 88 | 0.150 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2020 | 613 | 0.150 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 397 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2013 | 2805 | 0.150 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 6938 | 0.150 |
Why?
|
| Cyclin D | 2 | 2015 | 72 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2018 | 106 | 0.150 |
Why?
|
| Oncogenes | 2 | 2021 | 1222 | 0.150 |
Why?
|
| Young Adult | 15 | 2023 | 59260 | 0.150 |
Why?
|
| Gene Deletion | 1 | 2005 | 2665 | 0.150 |
Why?
|
| Fanconi Anemia | 1 | 2020 | 324 | 0.140 |
Why?
|
| Clinical Trials as Topic | 7 | 2015 | 8002 | 0.140 |
Why?
|
| Half-Life | 2 | 2015 | 651 | 0.140 |
Why?
|
| Thymine | 1 | 2017 | 68 | 0.140 |
Why?
|
| Trifluridine | 1 | 2017 | 28 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 257 | 0.140 |
Why?
|
| Gene Expression Profiling | 10 | 2018 | 9420 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2017 | 10090 | 0.130 |
Why?
|
| Photophobia | 1 | 2017 | 75 | 0.130 |
Why?
|
| Histones | 3 | 2023 | 2580 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1092 | 0.130 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2016 | 191 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2020 | 2872 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2020 | 1606 | 0.130 |
Why?
|
| Tumor Burden | 5 | 2015 | 1892 | 0.130 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 2209 | 0.130 |
Why?
|
| Tissue Distribution | 3 | 2019 | 2264 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 4 | 2013 | 3792 | 0.130 |
Why?
|
| RNA, Viral | 4 | 1988 | 2846 | 0.130 |
Why?
|
| Receptor, erbB-3 | 1 | 2016 | 143 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 552 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 605 | 0.130 |
Why?
|
| Cyclopentanes | 1 | 2015 | 87 | 0.130 |
Why?
|
| Influenza A virus | 3 | 1988 | 458 | 0.130 |
Why?
|
| Neutropenia | 3 | 2016 | 885 | 0.130 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2015 | 94 | 0.120 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 89 | 0.120 |
Why?
|
| Osteosarcoma | 3 | 2006 | 897 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 733 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 17 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2021 | 2048 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 954 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2015 | 116 | 0.120 |
Why?
|
| Metabolic Clearance Rate | 3 | 2011 | 361 | 0.120 |
Why?
|
| Pyrrolidines | 1 | 2017 | 338 | 0.120 |
Why?
|
| Keratoacanthoma | 1 | 2015 | 33 | 0.120 |
Why?
|
| Fatigue | 2 | 2012 | 1552 | 0.120 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 125 | 0.120 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 2016 | 0.120 |
Why?
|
| Cyclin D1 | 4 | 2016 | 451 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2020 | 2448 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2013 | 3492 | 0.120 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2014 | 86 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 517 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2023 | 2057 | 0.110 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 111 | 0.110 |
Why?
|
| Gene Amplification | 6 | 2020 | 1089 | 0.110 |
Why?
|
| Keratitis | 1 | 2017 | 241 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 802 | 0.110 |
Why?
|
| Cell Line, Transformed | 3 | 2006 | 866 | 0.110 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2018 | 328 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2013 | 1334 | 0.110 |
Why?
|
| Interferons | 3 | 2023 | 706 | 0.110 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2013 | 17 | 0.110 |
Why?
|
| Resorcinols | 1 | 2013 | 41 | 0.110 |
Why?
|
| Blotting, Western | 5 | 2016 | 5035 | 0.110 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 39106 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 598 | 0.110 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 422 | 0.110 |
Why?
|
| Rad51 Recombinase | 1 | 2013 | 189 | 0.110 |
Why?
|
| Receptors, Growth Factor | 2 | 2010 | 326 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 126 | 0.100 |
Why?
|
| Valine | 1 | 2014 | 408 | 0.100 |
Why?
|
| Biostatistics | 1 | 2014 | 164 | 0.100 |
Why?
|
| Oleanolic Acid | 1 | 2012 | 43 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2020 | 3639 | 0.100 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2012 | 66 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2012 | 105 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 168 | 0.100 |
Why?
|
| Organoids | 1 | 2018 | 746 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 3 | 2004 | 420 | 0.100 |
Why?
|
| Depsipeptides | 1 | 2012 | 95 | 0.100 |
Why?
|
| Cell Death | 3 | 2012 | 1679 | 0.100 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 7593 | 0.100 |
Why?
|
| Down-Regulation | 3 | 2018 | 2919 | 0.100 |
Why?
|
| Cross-Over Studies | 3 | 2012 | 2079 | 0.090 |
Why?
|
| Virus Replication | 3 | 1988 | 2435 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2021 | 2856 | 0.090 |
Why?
|
| Thoracic Neoplasms | 1 | 2013 | 267 | 0.090 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 422 | 0.090 |
Why?
|
| Ki-67 Antigen | 3 | 2015 | 629 | 0.090 |
Why?
|
| Biological Availability | 1 | 2011 | 390 | 0.090 |
Why?
|
| Sample Size | 1 | 2014 | 841 | 0.090 |
Why?
|
| Antiemetics | 1 | 2012 | 186 | 0.090 |
Why?
|
| Genes, bcl-2 | 1 | 2011 | 119 | 0.090 |
Why?
|
| Genes, cdc | 1 | 2011 | 114 | 0.090 |
Why?
|
| Sirolimus | 4 | 2013 | 1533 | 0.090 |
Why?
|
| Cell Line | 7 | 2020 | 15601 | 0.090 |
Why?
|
| Tumor Escape | 1 | 2013 | 370 | 0.090 |
Why?
|
| Substrate Specificity | 2 | 2012 | 1791 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2016 | 6228 | 0.090 |
Why?
|
| Protein Stability | 1 | 2012 | 578 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2006 | 319 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2013 | 360 | 0.090 |
Why?
|
| DNA Mutational Analysis | 4 | 2020 | 4111 | 0.090 |
Why?
|
| Benzazepines | 1 | 2012 | 310 | 0.090 |
Why?
|
| Mutagens | 1 | 2010 | 179 | 0.090 |
Why?
|
| Naphthyridines | 1 | 2011 | 143 | 0.090 |
Why?
|
| Survival Rate | 7 | 2023 | 12723 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2009 | 112 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2014 | 2510 | 0.080 |
Why?
|
| Cell Proliferation | 7 | 2024 | 10451 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 166 | 0.080 |
Why?
|
| Cohort Studies | 7 | 2023 | 41495 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2014 | 3165 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2012 | 507 | 0.080 |
Why?
|
| Mice, Nude | 6 | 2016 | 3614 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 5485 | 0.080 |
Why?
|
| Ifosfamide | 2 | 2023 | 232 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1704 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2016 | 13446 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2009 | 205 | 0.080 |
Why?
|
| Bone Neoplasms | 3 | 2006 | 2529 | 0.080 |
Why?
|
| Genes, Viral | 2 | 1987 | 649 | 0.080 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2023 | 4652 | 0.080 |
Why?
|
| Disease Models, Animal | 7 | 2018 | 18255 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 380 | 0.080 |
Why?
|
| Dideoxynucleosides | 1 | 2008 | 135 | 0.080 |
Why?
|
| Alanine | 1 | 2011 | 609 | 0.080 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2007 | 17 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 1420 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 10194 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2014 | 4317 | 0.070 |
Why?
|
| Paclitaxel | 5 | 2010 | 1732 | 0.070 |
Why?
|
| Kidney Neoplasms | 3 | 2014 | 4251 | 0.070 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2007 | 88 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1844 | 0.070 |
Why?
|
| NIH 3T3 Cells | 2 | 2008 | 670 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2012 | 744 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2014 | 783 | 0.070 |
Why?
|
| Protein Isoforms | 2 | 2016 | 1699 | 0.070 |
Why?
|
| RNA Polymerase II | 2 | 2013 | 539 | 0.070 |
Why?
|
| RNA Interference | 2 | 2013 | 2832 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2007 | 110 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 5821 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2010 | 791 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2023 | 2827 | 0.070 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 162 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1159 | 0.070 |
Why?
|
| Quinazolinones | 1 | 2007 | 221 | 0.070 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 1229 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2018 | 6567 | 0.060 |
Why?
|
| Thrombocytopenia | 3 | 2013 | 1182 | 0.060 |
Why?
|
| Orthomyxoviridae | 1 | 1987 | 149 | 0.060 |
Why?
|
| Cell Nucleus | 4 | 2012 | 2910 | 0.060 |
Why?
|
| Gene Duplication | 1 | 2006 | 314 | 0.060 |
Why?
|
| Positron-Emission Tomography | 5 | 2014 | 6484 | 0.060 |
Why?
|
| Disease Progression | 5 | 2012 | 13510 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2017 | 1416 | 0.060 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2005 | 188 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2013 | 1094 | 0.060 |
Why?
|
| Eating | 1 | 2011 | 1539 | 0.060 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 11122 | 0.060 |
Why?
|
| Leukemia | 1 | 2013 | 1522 | 0.060 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 3530 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2016 | 23996 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 2691 | 0.060 |
Why?
|
| Transcription Factor DP1 | 1 | 2003 | 136 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2017 | 20568 | 0.060 |
Why?
|
| RNA, Messenger | 8 | 2013 | 12794 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2016 | 53 | 0.060 |
Why?
|
| Drug Approval | 1 | 2010 | 814 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2004 | 283 | 0.050 |
Why?
|
| Proteomics | 2 | 2023 | 3848 | 0.050 |
Why?
|
| Templates, Genetic | 3 | 1988 | 189 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 250 | 0.050 |
Why?
|
| Gene Expression | 2 | 1999 | 7581 | 0.050 |
Why?
|
| E2F Transcription Factors | 1 | 2003 | 269 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6484 | 0.050 |
Why?
|
| Protein Binding | 2 | 2012 | 9353 | 0.050 |
Why?
|
| Lymphoma | 1 | 2012 | 1901 | 0.050 |
Why?
|
| Novobiocin | 1 | 2022 | 35 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8527 | 0.050 |
Why?
|
| Cell Division | 2 | 2007 | 4465 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1136 | 0.050 |
Why?
|
| Luciferases | 1 | 2004 | 714 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 1898 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 2297 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2004 | 412 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 2645 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 916 | 0.050 |
Why?
|
| Oximes | 1 | 2023 | 303 | 0.050 |
Why?
|
| Cytokines | 2 | 2013 | 7396 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2014 | 3779 | 0.050 |
Why?
|
| Hypertension | 2 | 2012 | 8540 | 0.050 |
Why?
|
| Chromatin | 2 | 2023 | 2961 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2013 | 1958 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 2457 | 0.050 |
Why?
|
| Taxoids | 2 | 2016 | 668 | 0.050 |
Why?
|
| Mice, Transgenic | 5 | 2013 | 9542 | 0.050 |
Why?
|
| Pyridazines | 1 | 2022 | 202 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 1640 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2001 | 353 | 0.040 |
Why?
|
| Anemia | 2 | 2013 | 1509 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2002 | 271 | 0.040 |
Why?
|
| Cell Movement | 4 | 2013 | 5205 | 0.040 |
Why?
|
| Cyclin A | 1 | 1999 | 60 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3597 | 0.040 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 2451 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 294 | 0.040 |
Why?
|
| Sarcoma | 1 | 2010 | 1801 | 0.040 |
Why?
|
| Purines | 1 | 2023 | 607 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.040 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 1858 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 4576 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 470 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2004 | 1134 | 0.040 |
Why?
|
| Cell Survival | 4 | 2011 | 5791 | 0.040 |
Why?
|
| DNA | 2 | 2022 | 7213 | 0.040 |
Why?
|
| Genotype | 1 | 2013 | 12990 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 56 | 0.040 |
Why?
|
| Base Sequence | 4 | 2016 | 12441 | 0.040 |
Why?
|
| Bronchi | 1 | 2002 | 845 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2023 | 2571 | 0.040 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1997 | 23 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2023 | 610 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 1997 | 40 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 621 | 0.040 |
Why?
|
| Sequence Deletion | 2 | 2007 | 1494 | 0.040 |
Why?
|
| Prednisone | 1 | 2022 | 1563 | 0.040 |
Why?
|
| Nervous System Neoplasms | 1 | 1997 | 91 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 2898 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2008 | 613 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2021 | 836 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2226 | 0.030 |
Why?
|
| Hyperphosphatemia | 1 | 2016 | 38 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2002 | 1646 | 0.030 |
Why?
|
| Translocation, Genetic | 2 | 2013 | 1393 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2020 | 764 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 795 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2707 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 1827 | 0.030 |
Why?
|
| Alleles | 1 | 2007 | 6864 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 5672 | 0.030 |
Why?
|
| Ovary | 1 | 2020 | 959 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2015 | 85 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2010 | 598 | 0.030 |
Why?
|
| Macrophages | 2 | 2020 | 5767 | 0.030 |
Why?
|
| DNA Primers | 2 | 2012 | 2820 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2010 | 3483 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2015 | 156 | 0.030 |
Why?
|
| Time Factors | 6 | 2012 | 39969 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 1654 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2021 | 1120 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 1997 | 564 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 1080 | 0.030 |
Why?
|
| Mitochondria | 1 | 2007 | 3624 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1995 | 777 | 0.030 |
Why?
|
| Caspases | 1 | 2017 | 879 | 0.030 |
Why?
|
| Dimerization | 1 | 2016 | 891 | 0.030 |
Why?
|
| Acrylamides | 1 | 2016 | 260 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2015 | 302 | 0.030 |
Why?
|
| Leukopenia | 1 | 2013 | 213 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1999 | 1342 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 1995 | 750 | 0.030 |
Why?
|
| Methylation | 1 | 1995 | 1084 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 496 | 0.030 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 2012 | 18 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1999 | 1601 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 1974 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 56 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 2469 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3514 | 0.020 |
Why?
|
| Etoposide | 1 | 2013 | 634 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2019 | 4399 | 0.020 |
Why?
|
| Ondansetron | 1 | 2012 | 95 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2012 | 127 | 0.020 |
Why?
|
| Nitrophenols | 1 | 2012 | 169 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 2467 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 629 | 0.020 |
Why?
|
| Phenotype | 3 | 2015 | 16592 | 0.020 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 188 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2020 | 80647 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2002 | 4142 | 0.020 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 487 | 0.020 |
Why?
|
| Stomatitis | 1 | 2013 | 271 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2012 | 248 | 0.020 |
Why?
|
| Tendons | 1 | 2015 | 558 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1093 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2023 | 2321 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 1990 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 738 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 17635 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 2021 | 0.020 |
Why?
|
| Recurrence | 2 | 2013 | 8466 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 592 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2010 | 115 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2002 | 3677 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2007 | 11530 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2010 | 186 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 6075 | 0.020 |
Why?
|
| Acetylation | 1 | 2012 | 1055 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1745 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2012 | 373 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 465 | 0.020 |
Why?
|
| Adolescent | 3 | 2023 | 88326 | 0.020 |
Why?
|
| Safety | 1 | 2014 | 1149 | 0.020 |
Why?
|
| Cell Transdifferentiation | 1 | 2010 | 186 | 0.020 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 2139 | 0.020 |
Why?
|
| Viral Proteins | 2 | 1987 | 1804 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2021 | 54423 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 1997 | 1699 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 413 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 5790 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 1250 | 0.020 |
Why?
|
| Drug Industry | 1 | 2014 | 788 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 535 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 185 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2010 | 578 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2012 | 1007 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2014 | 1088 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 36426 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 1749 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5247 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 1318 | 0.020 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2007 | 99 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 4740 | 0.020 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2006 | 84 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 1702 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 2643 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 1987 | 384 | 0.020 |
Why?
|
| Virion | 1 | 1988 | 422 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 89 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 664 | 0.020 |
Why?
|
| Viral Interference | 1 | 1985 | 12 | 0.020 |
Why?
|
| Lung | 2 | 2020 | 10002 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2915 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 4425 | 0.020 |
Why?
|
| Exons | 2 | 2006 | 2391 | 0.020 |
Why?
|
| Capsid | 1 | 1988 | 435 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 370 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 1023 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 1076 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 1987 | 526 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 4807 | 0.020 |
Why?
|
| Interleukin-3 | 1 | 2006 | 425 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2012 | 1948 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2007 | 712 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2006 | 491 | 0.010 |
Why?
|
| Genes, ras | 1 | 2007 | 654 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 4415 | 0.010 |
Why?
|
| Biopsy | 1 | 2016 | 6766 | 0.010 |
Why?
|
| Age Factors | 2 | 2017 | 18399 | 0.010 |
Why?
|
| Retroviridae | 1 | 2007 | 850 | 0.010 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2004 | 90 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2012 | 18966 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 2386 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2759 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3088 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2012 | 2490 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 393 | 0.010 |
Why?
|
| RNA | 2 | 1995 | 2725 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 3733 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1985 | 1762 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2004 | 342 | 0.010 |
Why?
|
| Linear Models | 1 | 2012 | 5872 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 1739 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2010 | 1250 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1987 | 1510 | 0.010 |
Why?
|
| Acute Disease | 1 | 2013 | 7237 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 4174 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2004 | 472 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1988 | 3094 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 6214 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4281 | 0.010 |
Why?
|
| Point Mutation | 1 | 2007 | 1595 | 0.010 |
Why?
|
| Interferon Type I | 1 | 1985 | 562 | 0.010 |
Why?
|
| Boston | 1 | 2014 | 9327 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 496 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4125 | 0.010 |
Why?
|
| Models, Biological | 1 | 2017 | 9469 | 0.010 |
Why?
|
| Skin | 1 | 2015 | 4484 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 2005 | 492 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 3597 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 1529 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 6312 | 0.010 |
Why?
|
| Patient Selection | 1 | 2011 | 4244 | 0.010 |
Why?
|
| Paxillin | 1 | 1999 | 86 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2009 | 5439 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4358 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2012 | 2332 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 5774 | 0.010 |
Why?
|
| Heart Rate | 1 | 2010 | 4195 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 1997 | 13 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 1997 | 66 | 0.010 |
Why?
|
| Tyrosine | 1 | 2002 | 1440 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2010 | 3879 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1085 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2002 | 1170 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12463 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1997 | 321 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3801 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 1997 | 225 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2004 | 1824 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15266 | 0.010 |
Why?
|
| Child | 1 | 2023 | 80158 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 22174 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2010 | 8481 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2008 | 3201 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 535 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1987 | 11904 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 5870 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 10212 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 14417 | 0.010 |
Why?
|
| Ligands | 1 | 1997 | 3272 | 0.010 |
Why?
|
| Research Design | 1 | 2004 | 6180 | 0.000 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1985 | 225 | 0.000 |
Why?
|
| Risk Factors | 1 | 2011 | 74213 | 0.000 |
Why?
|
| United States | 1 | 2011 | 72340 | 0.000 |
Why?
|